Cart
sales@molnova.com
Home -
Products -
Others -
Other Targets -
3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate
3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate
CAS No. 188649-48-1
3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate( ——— )
Catalog No. M39560 CAS No. 188649-48-1
3-((butyryloxy)methyl) 5-methyl 4-(2',3'-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 711 | In Stock |
|
| 25MG | Get Quote | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate
-
NoteResearch use only, not for human use.
-
Brief Description3-((butyryloxy)methyl) 5-methyl 4-(2',3'-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate
-
Description3-((butyryloxy)methyl) 5-methyl 4-(2',3'-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number188649-48-1
-
Formula Weight———
-
Molecular Formula———
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
2-[2-(2,2,2-Trifluor...
2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl methanesulfonate is a natural product that can be used as reference standards.
-
Neoruscogenin
Neoruscogenin represents a universal pharmacological tool for RORα research due to its specific selectivity profile versus other nuclear receptors.
-
Naringenin triacetat...
Naringenin triacetate exhibits a better binding affinity with multiple crystal structures of first bromodomain BRD4 (BRD4 BD1) when compared with the known inhibitors.
